Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Tetrahymena RIB72A and RIB72B are Microtubule Inner Proteins in the ciliary doublet microtubules.

Stoddard D, Zhao Y, Bayless BA, Gui L, Louka P, Dave D, Suryawanshi S, Tomasi RF, Dupuis-Williams P, Baroud CN, Gaertig J, Winey M, Nicastro D.

Mol Biol Cell. 2018 Aug 22:mbcE18060405. doi: 10.1091/mbc.E18-06-0405. [Epub ahead of print]

PMID:
30133348
2.

Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.

Passey C, Suryawanshi S, Sanghavi K, Gupta M.

AAPS J. 2018 Feb 26;20(2):35. doi: 10.1208/s12248-018-0194-9.

PMID:
29484520
3.

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.

Lee SH, Gantz I, Round E, Latham M, O'Neill EA, Ceesay P, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

BMC Endocr Disord. 2017 Nov 6;17(1):70. doi: 10.1186/s12902-017-0219-x.

4.

FRET Between Riboflavin and 9-Anthraldehyde Based Fluorescent Organic Nanoparticles Possessing Antibacterial Activity.

Mahajan PG, Dige NC, Suryawanshi SB, Dalavi DK, Kamble AA, Bhopate DP, Kadam AN, Kondalkar VV, Kolekar GB, Patil SR.

J Fluoresc. 2018 Jan;28(1):207-215. doi: 10.1007/s10895-017-2183-2. Epub 2017 Oct 27.

PMID:
29079896
5.

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.

Home P, Shankar RR, Gantz I, Iredale C, O'Neill EA, Jain L, Pong A, Suryawanshi S, Engel SS, Kaufman KD, Lai E.

Diabetes Res Clin Pract. 2018 Apr;138:253-261. doi: 10.1016/j.diabres.2017.10.018. Epub 2017 Oct 24.

6.

Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.

Gantz I, Sokolova L, Jain L, Iredale C, O'Neill EA, Wei Z, Lam R, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Clin Ther. 2017 Oct;39(10):2024-2037. doi: 10.1016/j.clinthera.2017.08.009. Epub 2017 Sep 18.

7.

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, Engel SS, Kaufman KD, Lai E.

Cardiovasc Diabetol. 2017 Sep 11;16(1):112. doi: 10.1186/s12933-017-0593-8.

8.

Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.

Suryawanshi SL, Shewade HD, Nagaraja SB, Nair SA, Parmar M.

Public Health Action. 2017 Jun 21;7(2):116-122. doi: 10.5588/pha.17.0013.

9.

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Curr Med Res Opin. 2017 Oct;33(10):1861-1868. doi: 10.1080/03007995.2017.1335638. Epub 2017 Jun 28.

PMID:
28548024
10.

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, Ceesay P, Suryawanshi S, Engel SS.

Curr Med Res Opin. 2017 Oct;33(10):1853-1860. doi: 10.1080/03007995.2017.1335637. Epub 2017 Jun 23.

PMID:
28547998
11.

Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.

Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, Vezina HE, McHenry MB, Waxman IM, Achanta A, Bello A, Roy A, Agrawal S.

Ann Oncol. 2017 Aug 1;28(8):2002-2008. doi: 10.1093/annonc/mdx235.

12.

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.

Wong H, Bohnert T, Damian-Iordache V, Gibson C, Hsu CP, Krishnatry AS, Liederer BM, Lin J, Lu Q, Mettetal JT, Mudra DR, Nijsen MJMA, Schroeder P, Schuck E, Suryawanshi S, Trapa P, Tsai A, Wang H, Wu F.

Drug Discov Today. 2017 Oct;22(10):1447-1459. doi: 10.1016/j.drudis.2017.04.015. Epub 2017 May 2. Review.

PMID:
28476536
13.

Carbazole based nanoprobe for selective recognition of Fe3+ ion in aqueous medium: Spectroscopic insight.

Suryawanshi SB, Mahajan PG, Bodake AJ, Kolekar GB, Patil SR.

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Aug 5;183:232-238. doi: 10.1016/j.saa.2017.04.010. Epub 2017 Apr 18.

PMID:
28454076
14.

A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E.

Int J Clin Pract. 2017 Jun;71(6). doi: 10.1111/ijcp.12955. Epub 2017 Apr 27.

PMID:
28449320
15.

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.

Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2017 Nov;19(11):1587-1593. doi: 10.1111/dom.12983. Epub 2017 Jul 7.

PMID:
28432745
16.
17.

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Apr;40(4):494-501. doi: 10.2337/dc16-1135. Epub 2017 Jan 5.

PMID:
28057693
18.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

19.

Gossypiboma: An Unusual Presentation as Perforation and Intraluminal Migration.

Tiwari VK, Mahey RK, Patil R, Bakale N, Suryawanshi S.

J Clin Diagn Res. 2016 Sep;10(9):PD01-PD02. Epub 2016 Sep 1.

20.

Identification and quantification of indoor air pollutant sources within a residential academic campus.

Suryawanshi S, Chauhan AS, Verma R, Gupta T.

Sci Total Environ. 2016 Nov 1;569-570:46-52. doi: 10.1016/j.scitotenv.2016.06.061. Epub 2016 Jun 18.

PMID:
27328399
21.

Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis.

Liao G, Zhou Z, Suryawanshi S, Mondal MA, Guo Z.

ACS Cent Sci. 2016 Apr 27;2(4):210-8. doi: 10.1021/acscentsci.5b00364. Epub 2016 Apr 4.

22.

A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.

Zhou Z, Liao G, Mandal SS, Suryawanshi S, Guo Z.

Chem Sci. 2015 Dec 1;6(12):7112-7121. Epub 2015 Sep 22.

23.

Antibiotic Prescribing Pattern in a Tertiary Level Neonatal Intensive Care Unit.

Suryawanshi S, Pandit V, Suryawanshi P, Panditrao A.

J Clin Diagn Res. 2015 Nov;9(11):FC21-4. doi: 10.7860/JCDR/2015/14764.6807. Epub 2015 Nov 1.

24.

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.

Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, Kaufman KD, Engel SS.

Diabetes Care. 2015 Nov;38(11):2106-14. doi: 10.2337/dc15-0109. Epub 2015 Aug 26.

PMID:
26310692
25.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM.

Pharmacol Res Perspect. 2015 Aug;3(4):e00159. doi: 10.1002/prp2.159. Epub 2015 Jul 6.

26.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

27.

Transbilayer lipid interactions mediate nanoclustering of lipid-anchored proteins.

Raghupathy R, Anilkumar AA, Polley A, Singh PP, Yadav M, Johnson C, Suryawanshi S, Saikam V, Sawant SD, Panda A, Guo Z, Vishwakarma RA, Rao M, Mayor S.

Cell. 2015 Apr 23;161(3):581-594. doi: 10.1016/j.cell.2015.03.048.

28.

Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.

Schuck E, Bohnert T, Chakravarty A, Damian-Iordache V, Gibson C, Hsu CP, Heimbach T, Krishnatry AS, Liederer BM, Lin J, Maurer T, Mettetal JT, Mudra DR, Nijsen MJ, Raybon J, Schroeder P, Schuck V, Suryawanshi S, Su Y, Trapa P, Tsai A, Vakilynejad M, Wang S, Wong H.

AAPS J. 2015 Mar;17(2):462-73. doi: 10.1208/s12248-014-9716-2. Epub 2015 Jan 29.

29.

Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents.

Tiwari A, Kumar S, Shivahare R, Kant P, Gupta S, Suryawanshi SN.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):410-3. doi: 10.1016/j.bmcl.2014.09.078. Epub 2014 Oct 2.

PMID:
25475205
30.

Spectral analysis of the emission current noise exhibited by few layer WS2 nanosheets emitter.

Suryawanshi SR, Kolhe PS, Rout CS, Late DJ, More MA.

Ultramicroscopy. 2015 Feb;149:51-7. doi: 10.1016/j.ultramic.2014.10.004. Epub 2014 Oct 29.

PMID:
25436929
31.

Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RP, Vlad AM.

Clin Cancer Res. 2014 Dec 1;20(23):6163-74. doi: 10.1158/1078-0432.CCR-14-1338. Epub 2014 Oct 7.

32.

Vapor-liquid-solid growth of one-dimensional tin sulfide (SnS) nanostructures with promising field emission behavior.

Suryawanshi SR, Warule SS, Patil SS, Patil KR, More MA.

ACS Appl Mater Interfaces. 2014 Feb 12;6(3):2018-25. doi: 10.1021/am405039j. Epub 2014 Jan 27.

PMID:
24432697
33.

Bioavailability enhancement of ondansetron after nasal administration of Caesalpinia pulcherrima-based microspheres.

Suryawanshi SR, Thakare NP, More DP, Thombre NA.

Drug Deliv. 2015;22(7):894-902. doi: 10.3109/10717544.2013.860205. Epub 2013 Nov 26.

PMID:
24279581
34.

Design, synthesis and biological evaluation of aryl pyrimidine derivatives as potential leishmanicidal agents.

Suryawanshi SN, Kumar S, Shivahare R, Pandey S, Tiwari A, Gupta S.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5235-8. doi: 10.1016/j.bmcl.2013.06.060. Epub 2013 Jun 29.

PMID:
23910597
35.

Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.

Suryawanshi SN, Kumar S, Tiwari A, Shivahare R, Chhonker YS, Pandey S, Shakya N, Bhatta RS, Gupta S.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3979-82. doi: 10.1016/j.bmcl.2013.04.025. Epub 2013 Apr 26.

PMID:
23673014
36.

Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents.

Suryawanshi SN, Tiwari A, Kumar S, Shivahare R, Mittal M, Kant P, Gupta S.

Bioorg Med Chem Lett. 2013 May 15;23(10):2925-8. doi: 10.1016/j.bmcl.2013.03.055. Epub 2013 Mar 26.

PMID:
23582274
37.

Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.

Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X.

Clin Cancer Res. 2013 Mar 1;19(5):1213-24. doi: 10.1158/1078-0432.CCR-12-2726. Epub 2013 Jan 29.

38.

Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles.

Tiwari A, Kumar S, Suryawanshi SN, Mittal M, Vishwakarma P, Gupta S.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):248-51. doi: 10.1016/j.bmcl.2012.10.110. Epub 2012 Nov 2.

PMID:
23177254
39.

Chemotherapy of leishmaniasis. Part XI: synthesis and bioevaluation of novel isoxazole containing heteroretinoid and its amide derivatives.

Suryawanshi SN, Tiwari A, Chandra N, Ramesh, Gupta S.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6559-62. doi: 10.1016/j.bmcl.2012.09.024. Epub 2012 Sep 15.

PMID:
23031597
40.

Chemotherapy of leishmaniasis. Part IX: synthesis and bioevaluation of aryl substituted ketene dithioacetals as antileishmanial agents.

Kumar S, Tiwari A, Suryawanshi SN, Mittal M, Vishwakarma P, Gupta S.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6728-30. doi: 10.1016/j.bmcl.2012.08.096. Epub 2012 Sep 13.

PMID:
23031588
41.

Left atrial spindle cell sarcoma - case report.

Mehta N, Desai A, Shivdasani B, Suryawanshi S, Mehta AB, Behranwala A, Dhabhar B.

Indian Heart J. 2012 Jul-Aug;64(4):416-9. doi: 10.1016/j.ihj.2012.06.008. Epub 2012 Jun 22.

42.

Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.

Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T.

Curr Med Res Opin. 2012 Aug;28(8):1289-96. doi: 10.1185/03007995.2012.707119. Epub 2012 Jul 6.

PMID:
22738801
43.

Serum ferritin-a novel risk factor in acute myocardial infarction.

Holay MP, Choudhary AA, Suryawanshi SD.

Indian Heart J. 2012 Mar-Apr;64(2):173-7. doi: 10.1016/S0019-4832(12)60056-X. Epub 2012 Apr 28.

44.

Total synthesis of sialic acid by a sequential rhodium-catalyzed aziridination and Barbier allylation of D-glycal.

Lorpitthaya R, Suryawanshi SB, Wang S, Pasunooti KK, Cai S, Ma J, Liu XW.

Angew Chem Int Ed Engl. 2011 Dec 9;50(50):12054-7. doi: 10.1002/anie.201104516. Epub 2011 Oct 18. No abstract available.

PMID:
22006859
45.

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS; 2010 Ramadan Study Group.

Int J Clin Pract. 2011 Nov;65(11):1132-40. doi: 10.1111/j.1742-1241.2011.02797.x. Epub 2011 Sep 27.

46.

Left main coronary artery atresia: the role of computed tomographic coronary angiography.

Srinivas B, Suryawanshi SP, Seshagiri RD.

Pediatr Cardiol. 2011 Dec;32(8):1262-3. doi: 10.1007/s00246-011-0081-y. Epub 2011 Aug 9. No abstract available.

PMID:
21826522
47.

Clinical and statistical assessment of suicidal ideation and behavior in pharmaceutical trials.

Gassmann-Mayer C, Jiang K, McSorley P, Arani R, Dubrava S, Suryawanshi S, Webb DM, Nilsson M.

Clin Pharmacol Ther. 2011 Oct;90(4):554-60. doi: 10.1038/clpt.2011.144. Epub 2011 Jul 20. Review.

PMID:
21775982
48.

Association of impaired cognitive functions with cardiovascular risk factors in elderly Indian population.

Holay MP, Patil PS, Joshi PP, Dube AM, Suryawanshi SD, Waradkar P.

J Assoc Physicians India. 2011 Feb;59:91-4.

PMID:
21751643
49.

Myocardial infarction in children: Two interesting cases.

Suryawanshi SP, Das B, Patnaik AN.

Ann Pediatr Cardiol. 2011 Jan;4(1):81-3. doi: 10.4103/0974-2069.79633.

50.

Preclinical pharmacokinetics, dose proportionality, gender difference and protein binding study of 16-dehydropregnenolone, an antihyperlipidemic agent, in rats.

Suryawanshi S, Wahajuddin, Gupta RC, Singh SK.

J Pharm Pharmacol. 2011 Jan;63(1):41-8. doi: 10.1111/j.2042-7158.2010.01158.x. Epub 2010 Oct 11.

PMID:
21155814

Supplemental Content

Loading ...
Support Center